SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart - Li, Chenguang; Zhang, Jie; Xue, Mei; Li, Xiaoyu; Han, Fei; Liu, Xiangyang; Xu, Linxin; Lu, Yunhong; Cheng, Ying; Li, Ting; Yu, Xiaochen; Sun, Bei; et al. (Cardiovascular diabetology, 2019)
Keywords: Animals; Antidiabetics; Antioxidant Response Elements; Antioxidants; Antioxidants - pharmacology; Apoptosis; Benzhydryl Compounds - pharmacology; Cardiomyopathy; Cardiovascular disease; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Diabetic Cardiomyopathies - etiology; Diabetic Cardiomyopathies - metabolism; Diabetic Cardiomyopathies - physiopathology; Diabetic Cardiomyopathies - prevention & control; Disease Models, Animal; Echocardiography; Empagliflozin; Fibrosis; Glucose; Glucosides - pharmacology; Growth factors; Heart; Hyperglycemia; Immunohistochemistry; Insulin; Mice, Inbred C57BL; Myocardial fibrosis; Myocardium; Myocardium - metabolism; Myocardium - pathology; NF-E2-Related Factor 2 - metabolism; Original Investigation; Oxidants; Oxidative stress; Oxidative Stress - drug effects; Phosphorylation; Rodents; SGLT2; Signal Transduction - drug effects; Smad protein; Smad Proteins - metabolism; Sodium; Sodium-glucose cotransporter; Sodium-Glucose Transporter 2 - metabolism; Sodium-Glucose Transporter 2 Inhibitors - pharmacology; Structure-function relationships; Transforming growth factor; Transforming Growth Factor beta1 - metabolism; Transforming growth factor-b; Type 2 diabetes mellitus; Uric acid; Ventricular Function, Left - drug effects; Ventricular Remodeling - drug effects; Beijing China; China; Empagliflozin; Oxidative stress; Myocardial fibrosis; Type 2 diabetes mellitus; SGLT2